Table 4.

Scenario results

Scenario	Incremental cost-effectiveness ratio
Squamous scenario analyses
Overall survival extrapolation: spline normal 2-knot distribution	£38,888
Treatment effect of nivolumab continues for 3 years following treatment discontinuation	£36,249
Trial-based utility values	£33,134
Non-squamous scenario analyses
Overall survival extrapolation: spline hazard 3-knot distribution	£33,832
Treatment effect of nivolumab continues for 3 years following treatment discontinuation	£39,848
Trial-based utility values	£37,582